NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)

Phase 2

Terminated

Conditions: Anatomic Stage IV Breast Cancer AJCC v8
Metastatic HER2-Negative Breast Carcinoma
Metastatic Hormone Receptor-Positive Breast Carcinoma

Interventions: Drug: Binimetinib
Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Bone Scan
Procedure: Computed Tomography
Procedure: Echocardiography Test
Drug: Fulvestrant
Procedure: Magnetic Resonance Imaging
Procedure: Multigated Acquisition Scan

First Posted Date: 2022-09-26

Last Posted Date: 2025-04-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 1

Registration Number: NCT05554354

Locations: 🇺🇸
VCU Community Memorial Health Center, South Hill, Virginia, United States
🇺🇸
Carle at The Riverfront, Danville, Illinois, United States
🇺🇸
UI Health Care Mission Cancer and Blood - Ankeny Clinic, Ankeny, Iowa, United States

and more 193 locations

Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial

Phase 2

Active, not recruiting

Conditions: Metastatic Malignant Solid Neoplasm
Refractory Malignant Solid Neoplasm

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Drug: Nilotinib Hydrochloride Monohydrate
Drug: Paclitaxel

First Posted Date: 2022-09-26

Last Posted Date: 2025-04-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT05554341

Locations: 🇺🇸
Carle at The Riverfront, Danville, Illinois, United States
🇺🇸
Cancer Care Specialists of Illinois - Decatur, Decatur, Illinois, United States
🇺🇸
Decatur Memorial Hospital, Decatur, Illinois, United States

and more 123 locations

Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)

Phase 2

Not yet recruiting

Conditions: Secondary Acute Myeloid Leukemia
Acute Myeloid Leukemia
Acute Myeloid Leukemia Post Cytotoxic Therapy
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Acute Myeloid Leukemia Arising From Previous Myeloproliferative Neoplasm

Interventions: Procedure: Bone Marrow Aspiration and Biopsy
Drug: Azacitidine
Drug: Cytarabine
Procedure: Echocardiography Test
Drug: Liposome-encapsulated Daunorubicin-Cytarabine
Procedure: Multigated Acquisition Scan
Drug: Venetoclax

First Posted Date: 2022-09-26

Last Posted Date: 2025-05-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 184

Registration Number: NCT05554419

Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial

Phase 2

Recruiting

Conditions: Ovarian Low Grade Serous Adenocarcinoma
Exocrine Pancreas Carcinoma
Stage IV Ovarian Cancer AJCC v8
Malignant Solid Neoplasm
Stage IV Pancreatic Cancer AJCC v8

Interventions: Drug: Binimetinib
Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Bone Scan
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Drug: Palbociclib

First Posted Date: 2022-09-26

Last Posted Date: 2025-05-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 199

Registration Number: NCT05554367

Locations: 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸
Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois, United States
🇺🇸
Illinois CancerCare - Washington, Washington, Illinois, United States

and more 260 locations

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Phase 2

Recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Azacitidine
Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Drug: Cytarabine
Drug: Daunorubicin Hydrochloride
Drug: Venetoclax

First Posted Date: 2022-09-26

Last Posted Date: 2025-05-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 153

Registration Number: NCT05554393

Locations: 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸
Banner University Medical Center - Tucson, Tucson, Arizona, United States
🇺🇸
University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States

and more 132 locations

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

Phase 2

Recruiting

Conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm
Acute Myeloid Leukemia Post Cytotoxic Therapy
Acute Myeloid Leukemia
Acute Myeloid Leukemia, Myelodysplasia-Related

Interventions: Procedure: Biospecimen Collection
Drug: Azacitidine
Procedure: Bone Marrow Aspiration
Drug: Cytarabine
Drug: Daunorubicin Hydrochloride
Drug: Liposome-encapsulated Daunorubicin-Cytarabine
Procedure: Echocardiography Test
Procedure: Multigated Acquisition Scan
Drug: Venetoclax

First Posted Date: 2022-09-26

Last Posted Date: 2025-05-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 335

Registration Number: NCT05554406

Locations: 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸
Banner University Medical Center - Tucson, Tucson, Arizona, United States
🇺🇸
University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States

and more 157 locations

Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With AKT Mutations, A ComboMATCH Treatment Trial

Phase 2

Recruiting

Conditions: Locally Advanced Malignant Solid Neoplasm
Metastatic Malignant Solid Neoplasm
Unresectable Malignant Solid Neoplasm

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Ipatasertib
Procedure: Magnetic Resonance Imaging
Drug: Paclitaxel

First Posted Date: 2022-09-26

Last Posted Date: 2025-05-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 33

Registration Number: NCT05554380

Locations: 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸
University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States
🇺🇸
Alaska Women's Cancer Care, Anchorage, Alaska, United States

and more 204 locations

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

Phase 2

Recruiting

Conditions: Recurrent Endometrial Carcinoma
Recurrent Fallopian Tube Carcinoma
Recurrent Ovarian Carcinoma
Recurrent Primary Peritoneal Carcinoma

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration and Biopsy
Procedure: Computed Tomography
Procedure: Echocardiography Test
Procedure: Multigated Acquisition Scan
Drug: Olaparib
Drug: Selumetinib Sulfate

First Posted Date: 2022-09-26

Last Posted Date: 2025-05-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 165

Registration Number: NCT05554328

Locations: 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸
University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States
🇺🇸
Alaska Women's Cancer Care, Anchorage, Alaska, United States

and more 265 locations

The Effects of Increasing Caloric Intake on Diet-Induced Thermogenesis and 24h Energy Expenditure

Not Applicable

Recruiting

Conditions: Healthy Volunteers
Normal Physiology
Obesity

Interventions: Dietary Supplement: +200% of dietary requirements, 50% of calories from carbohydrates, 20% from protein, and 30% from fat
Dietary Supplement: fasting
Dietary Supplement: -50% of energy balance requirements. 50% of calories from carbohydrates, 20% from protein, and 30% from fat
Dietary Supplement: +150% of energy balance requirements, 50% of calories from carbohydrates, 20% from protein, and 30% from fat
Dietary Supplement: +200% of dietary requirements, 51% of the calories from carbohydrates, 46%, from fat and 3% from protein
Dietary Supplement: -25% of energy balance requirements, 50% of calories from carbohydrates, 20% from protein, and 30% from fat
Dietary Supplement: +150% of dietary requirements, 51% of the calories from carbohydrates, 46%, from fat and 3% from protein

First Posted Date: 2022-09-19

Last Posted Date: 2025-04-24

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 120

Registration Number: NCT05545306

Locations: 🇺🇸
NIDDK, Phoenix, Phoenix, Arizona, United States

Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers

Phase 1

Recruiting

Conditions: FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma
FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma
Metastatic Endometrial Endometrioid Adenocarcinoma
Recurrent Endometrial Endometrioid Adenocarcinoma

Interventions: Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Ipatasertib
Procedure: Magnetic Resonance Imaging
Drug: Megestrol Acetate

First Posted Date: 2022-09-14

Last Posted Date: 2025-05-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 96

Registration Number: NCT05538897

Locations: 🇺🇸
Banner University Medical Center - Tucson, Tucson, Arizona, United States
🇺🇸
University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
🇺🇸
Highlands Oncology Group - Fayetteville, Fayetteville, Arkansas, United States

and more 148 locations

Home Terms & Conditions Privacy Policy